Skip to main content
NEXTBIOMEDICAL Co., Ltd. logo

NEXTBIOMEDICAL Co., Ltd. — Investor Relations & Filings

Ticker · 389650 ISIN · KR7389650003 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country KR South Korea
Listing KO 389650

About NEXTBIOMEDICAL Co., Ltd.

https://nextbiomedical.co.kr/en/

NEXTBIOMEDICAL Co., Ltd. is a company specializing in the development and commercialization of innovative therapeutic solutions, with a focus on drug-device combination products. The company's core competency is its proprietary polymer technology platform, which includes biodegradable adhesive polymers and resorbable microspheres. These technologies are applied to create first-in-class medical devices that address unmet clinical needs. Key product applications include advanced hemostatic agents for endoscopic procedures and embolic materials for interventional pain management and vascular therapies, such as genicular artery embolization for osteoarthritis pain.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (NexsphereF 일본 독점 판권 계약)
Regulatory Filings Classification · 1% confidence The document is a corporate disclosure in Korean titled “투자판단 관련 주요경영사항” describing a licensing/distribution agreement (Nexsphere-F™ Japan exclusive rights) with Asahi Intecc. It is not an AGM material, annual or interim report, audit or earnings release, nor is it about dividends, board changes, share issues, M&A, or insider trades. It is a standalone announcement of a major contract that does not fall under financing, share transactions, or any other defined specific category. Therefore, it is classified under the fallback “Regulatory Filings” (RNS).
2026-04-09 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is the official results of an annual general meeting held on March 30, 2026. It lists agenda items, voting outcomes, approval of financial statements, election of auditors and directors, and detailed vote percentages for each resolution. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), where formal shareholder vote results are disclosed.
2026-03-30 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). The document contains detailed corporate information, including board of directors, management, shareholding, and business activities, and explicitly states it is a correction to the previously submitted Annual Report. According to the classification rules, this is a comprehensive financial report filing. FY 2025
2026-03-20 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 12th fiscal year (2025) of NextBiomedical Co., Ltd. It contains comprehensive company information, including business overview, history, capital structure, and management details, which are characteristic of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It contains the auditor's opinion, financial statements, and details regarding the audit process for the fiscal year ending 2025-12-31. While it provides financial data, it is specifically the regulatory notification of the audit report's submission rather than the full annual report (10-K) or a standalone audit report (AR). In the context of Korean regulatory filings (DART/KIND), this is a standard disclosure of the audit results. Given the provided categories, 'AR' (Audit Report / Information) is the most accurate classification for a document detailing audit opinions and financial results verified by an external auditor. FY 2025
2026-03-19 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to provide shareholders with information regarding upcoming general meetings and to solicit their votes. It contains details on the meeting agenda, director/auditor candidates, executive compensation, and voting procedures. This fits the definition of a Proxy Solicitation & Information Statement.
2026-03-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.